Related Experiment Video
Updated: Jun 25, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Insulin analog therapy: improving the match with physiologic insulin secretion
1Division of Endocrinology and Metabolism, Philadelphia College of Osteopathic Medicine, Philadelphia, PA 19131-1633, USA. jeffreyfreemando@aol.com
The Journal of the American Osteopathic Association
|February 6, 2009
Summary
Insulin analogs offer improved treatment convenience and reduced hypoglycemia for type 2 diabetes patients. These advancements may enhance adherence and improve glycemic control, leading to better patient outcomes.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes mellitus affects a growing population, with many patients not meeting glycemic targets.
- Suboptimal glycemic control increases the risk of diabetes-related complications.
Observation:
- Rapid-acting insulin analogs (aspart, lispro, glulisine) offer pharmacokinetic profiles closer to endogenous insulin.
- Long-acting insulin analogs (detemir, glargine) provide a more precise simulation of basal insulin secretion.
- Insulin analogs can be administered closer to mealtimes and reduce hypoglycemia risk.
Findings:
- Insulin analogs demonstrate improved physiologic profiles and greater convenience compared to human insulins.
- Therapy with insulin analogs is associated with a reduced risk of hypoglycemia.
- Some insulin analogs may lead to less weight gain in patients.
Implications:
- Enhanced convenience and reduced hypoglycemia risk can improve patient adherence to insulin therapy.
- Increased treatment adherence may lead to better glycemic control in type 2 diabetes.
- Improved glycemic control and adherence can positively impact the long-term prognosis for patients.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...